Skip to main content

Table 3 Nab-paclitaxel’s ongoing trials phase III and important phase II trials as listed below

From: Emerging therapies for breast cancer

CT.gov No.

Phase

Investigational Agent

Trial

Setting

n

Completion Date

NCT02620280

III

Atezolizumab

Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin (NeoTRIPaPDL1)

Neoadjuvant TNBC

272

2022

NCT02425891

III

Atezolizumab

A study of atezolizumab in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for participants with previously untreated metastatic triple negative breast cancer (IMpassion130)

mTNBC

900

2020

NCT02819518

III

Pembrolizumab

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)

Locally recurrent or metastatic BC

858

2019

NCT01690702

III

Epirubicin, Cyclophosphamide Docetaxel

Adjuvant Phase III Trial to Compare Intense Dose-dense Adjuvant Treatment With EnPC to Dose Dense, Tailored Therapy With dtEC-dtD for Patients With High-risk Early Breast Cancer (GAIN-2)

Adjuvant high risk BC

2886

2020

CBCSG018

II

Gemcitabine

A randomized phase 2 trial of weekly nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment for patients with metastatic triple-negative breast cancer

mTNBC

254

2018

Cisplatin

NCT02685059

II

Durvalumab

A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Neoadjuvant TNBC

174

2018

NCT02783222

II

nab-paclitaxel

A Randomized Phase II Study to Evaluate the EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly Patients With advanCed breasT Cancer (EFFECT)

≥65y Locally recurrent or metastatic BC

156

2017